News
New alliance with Gilead Sciences is ‘transformative’
When Robert J. Alpern, M.D., dean of the School of Medicine, was asked recently to prepare a brief overview of the current state of drug discovery for a symposium at Yale’s West Campus, a familiar phrase came quickly to mind: “It was the best of times, it was the worst of times ...” It’s an apt description. On the one hand, we live in what some call the “post-Gleevec era,” a time when basic research conducted over decades is bearing fruit in the form of remarkably effective, targeted drugs.